Karyopharm Therapeutics KPT-9274 had its Phase Transition Success Rate (PTSR) plummet in multiple oncology indications due to the termination of a Phase I basket trial recruiting patients with solid tumours and non-Hodgkin’s lymphoma (NHL). KPT-9274’s PTSR dropped by 21 points in melanoma to 11% and 14 points to 8% in colon cancer. It also dived by 18 points and 21 points in NHL and sarcomas, respectively, to 14% and 11%.
The Phase I PANAMA trial’s (NCT02702492) status was updated on 25 June from recruiting to sponsor-decided termination. The PTSR was updated on 29 June. PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next.
KPT-9274 is a dual inhibitor of PAK4 (p21 activated kinase) and NAMPT (nicotinamide phosphoribosyltransferase), with this inhibition approach designed to trigger cancer cell apoptosis. PANAMA was primarily investigating for KPT-9274 maximum tolerated dose as a monotherapy and in combination with either niacin or Bristol Myers Squibb’s Opdivo (nivolumab).
KPT-9274’s Likelihood of Approval (LoA) also declined on the back of the PANAMA trial’s termination, ranging from 6 points to 4% in NHL to 1 point to 0% in colon cancer. LoA is identified via GlobalData’s analysis using a combination of machine learning and its proprietary algorithm.
Karyopharm has a market cap of $775m.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Reynald Castaneda is an Associate Editor for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.